You are here

A Risk Evaluation and Mitigation Strategy (REMS) to manage the risks of overdose, abuse, addiction, and diversion with rapid-onset opioids

R. Kaper, J. Schmider, R. Bradway, E. Floyd

The Journal of Pain, Volume 11, Issue 4, Supplement, April 2010, pS23

Abstract:
A Risk Evaluation and Mitigation Strategy (REMS), formalized in the Food and Drug Administration Amendments Act (FDAAA) in 2007, is a regulatory strategy to manage a known or potential serious risk. This presentation describes a REMS model developed for the rapid-onset opioids fentanyl buccal tablet (FBT) and oral transmucosal fentanyl citrate (OTFC). In response to requirements delineated by FDA, the model includes elements to assure safe use, a medication guide, an implementation system, and a timetable for assessment.

Search form


E-Alert

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre


What do you think?

Please take a moment to fill out our reader survey.

Read more